Course of Vitamin D Levels in Newly Diagnosed Non-Metastatic Breast Cancer Patients over One Year with Quarterly Controls and Substitution
Authors:
- Cosima ZemlinCZCosima Zemlin
- Laura AltmayerLALaura Altmayer
- Marina LangMLMarina Lang
- Julia Theresa SchleicherJSJulia Theresa Schleicher
- Caroline StuhlertCSCaroline Stuhlert
- Carolin WörmannCWCarolin Wörmann
- Laura-Sophie SchererLSLaura-Sophie Scherer
- Ida Clara ThulITIda Clara Thul
- Lisanne Sophie SpennerLSLisanne Sophie Spenner
- Jana Alisa SimonJSJana Alisa Simon
- Alina WindAWAlina Wind
- Elisabeth KaiserEKElisabeth Kaiser
Open Access
Abstract
(1) Background: Vitamin D levels in patients remain inadequately understood, with research yielding inconsistent findings. Breast cancer patients, particularly due to oncological therapies, face an increased risk of osteopenia, which can be exacerbated by a vitamin D deficiency. (2) Methods: The prospective observational “BEGYN-1” study assessed serum 25(OH)D levels at baseline and quarterly thereafter. Clinical, pathological, nutritional, vitamin supplementation, and lifestyle data were recorded. (3) Results: Before treatment, 68.5% of patients were vitamin D deficient (<30 ng/mL), with 4.6% experiencing severe deficiency (<10 ng/mL). The median baseline 25(OH)D levels were 24 ng/mL (range: 4.8 to 64.7 ng/mL). Throughout the study, the median vitamin D levels increased to 48 ng/mL (range: 22.0 to 76.7 ng/mL). Before diagnosis, 16.7% received vitamin D substitution, and 97.8% received vitamin D substitution throughout the year with a median weekly dose of 20,000 IU. It took at least three quarterly assessments for 95% of patients to reach the normal range. A multiple GEE analysis identified associations between 25(OH)D levels and supplementation, season, age, VLDL, magnesium levels, and endocrine therapy. (4) Conclusions: Physicians should monitor 25(OH)D levels before, during, and after oncological therapy to prevent vitamin D deficiency and to adjust substitution individually. While variables such as seasons, age, VLDL, magnesium, diet, and oncological interventions affect 25(OH)D levels, supplementation has the greatest impact.Keywords
Funding Information
- miteinander gegen Krebs e.V. (E204160128, W/2—LFFP 21/13, MU 4812/2-1:2)
- a grant from the federal state of Saarland (E204160128, W/2—LFFP 21/13, MU 4812/2-1:2)
- Deutsche Forschungsgemeinschaft (E204160128, W/2—LFFP 21/13, MU 4812/2-1:2)
This publication has 53 references indexed in Scilit:
- Vitamin D Knowledge, Awareness, and Attitudes of Adolescents and Adults: A Systematic ReviewJournal of Nutrition Education and Behavior, 2023
- Cytotoxic chemotherapy is associated with decreased bone mineral density in postmenopausal women with early and locally advanced breast cancerArchives of Osteoporosis, 2023
- Vitamin D food fortification in European countries: the underused potential to prevent cancer deathsEuropean Journal of Epidemiology, 2022
- The effect of combined magnesium and vitamin D supplementation on vitamin D status, systemic inflammation, and blood pressure: A randomized double-blinded controlled trialNutrition, 2022
- Vitamin D UpdateCurrent Dermatology Reports, 2020
- Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathyBreast Cancer Research and Treatment, 2020
- Vitamin D: And its role in breast cancerThe Kaohsiung Journal of Medical Sciences, 2018
- Changes in serum hydroxyvitamin D levels of breast cancer patients during tamoxifen treatment or chemotherapy in premenopausal breast cancer patientsEuropean Journal of Cancer, 2014
- The effect of vitamin D supplementation on serum 25OHD in thin and obese womenThe Journal of Steroid Biochemistry and Molecular Biology, 2013
- Genetic Variants and Associations of 25-Hydroxyvitamin D Concentrations With Major Clinical OutcomesJAMA, 2012